Your browser is no longer supported. Please, upgrade your browser.
PFE Pfizer Inc. daily Stock Chart
Pfizer Inc.
IndexDJIA S&P500 P/E28.82 EPS (ttm)1.13 Insider Own0.04% Shs Outstand6.13B Perf Week-0.18%
Market Cap199.22B Forward P/E12.14 EPS next Y2.68 Insider Trans-30.80% Shs Float6.05B Perf Month-4.44%
Income6.99B PEG4.65 EPS next Q0.62 Inst Own71.70% Short Float0.72% Perf Quarter-11.22%
Sales52.29B P/S3.81 EPS this Y-21.50% Inst Trans-0.02% Short Ratio2.27 Perf Half Y1.02%
Book/sh10.34 P/B3.14 EPS next Y8.82% ROA4.20% Target Price39.20 Perf Year-5.09%
Cash/sh3.41 P/C9.51 EPS next 5Y6.20% ROE10.90% 52W Range27.77 - 37.08 Perf YTD3.39%
Dividend1.20 P/FCF32.93 EPS past 5Y1.60% ROI7.30% 52W High-13.27% Beta0.89
Dividend %3.69% Quick Ratio1.10 Sales past 5Y-5.60% Gross Margin77.80% 52W Low15.81% ATR0.41
Employees97900 Current Ratio1.40 Sales Q/Q-42.10% Oper. Margin17.60% RSI (14)32.47 Volatility1.15% 1.18%
OptionableYes Debt/Eq0.70 EPS Q/Q-58.80% Profit Margin13.40% Rel Volume1.24 Prev Close32.48
ShortableYes LT Debt/Eq0.49 EarningsNov 01 BMO Payout101.70% Avg Volume19.19M Price32.16
Recom2.30 SMA20-2.46% SMA50-4.98% SMA200-1.90% Volume1,649,209 Change-0.99%
Oct-13-16Downgrade Jefferies Buy → Hold
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Oct-28-16 09:16AM  Pfizer calls piling up before earnings
08:04AM  New Label Expansion May Help Boost Sutents Growth Prospects
06:59AM  [$$] Aggressive tax avoidance raises risks for investors at Financial Times
Oct-27-16 04:08PM  The Woman At The Center Of The Biggest Biotech IPO Of The Year at Forbes
11:37AM  Pfizer (PFE) to Post Q3 Earnings: How Will the Stock React?
11:04AM  Inlyta Expected to Witness Competitive Pressures in 2016
10:05AM  Xalkori Label Expansion May Boost Pfizers Sales in 2016
08:56AM  Biggest Biotech IPO Of 2016 Is Launched By 31 Year Old at Forbes
08:05AM  Pfizer Continues to Work on Ibrance Label Expansion in 2016
08:04AM  Pfizer Expects Ibrance to Become a Blockbuster Therapy
07:02AM  Better Buy: Eli Lilly and Co vs. Pfizer at Motley Fool
06:00AM  'Mad Money' Lightning Round: Dollar Tree Has 'Been in Free Fall'
Oct-26-16 07:28PM  Cramer: This sector will bounce back after the election at CNBC
06:16PM  How Do Pfizers Valuation Multiples Compare with Those of Other Oncology Players in 2016?
11:04AM  Xeljanz ER Is Driving Growth for Pfizer This Year
10:04AM  Enbrel Facing Competition from Biosimilar Versions of the Drug
09:30AM  The Zacks Analyst Blog Highlights: AT&T, General Mills, Pfizer and Time Warner
08:04AM  Interesting Trend Developing for Pfizers Pneumococcal Franchise
07:40AM  Short Sellers Grow More Selective on Major Pharma Stocks at 24/7 Wall St.
Oct-25-16 07:22PM  Ex-Oppenheimer & Co. worker pleads guilty to insider trading
05:48PM  Ex-Oppenheimer adviser pleads guilty to U.S. insider trading charges
04:06PM  Ex-Oppenheimer adviser to plead guilty in U.S. to insider trading
01:04PM  How Much Revenue Growth Could Novo Record in 3Q16?
12:36PM  Analyst Reports for AT&T, Pfizer & General Mills
11:45AM  Bristol-Myers Squibbs 3Q16 Earnings: Whats Expected
11:04AM  Viagra May Witness a Decline in Revenues in 2016
10:04AM  Update on Roches Analyst Recommendations
10:04AM  Pfizer Has a Revenue-Boosting Treatment to Help Smokers Quit
08:37AM  Merck Keytruda Gets FDA Approval for First-Line Lung Cancer
08:04AM  Toviaz Expected to Report Stable Revenues in 2016
Oct-24-16 04:19PM  Ariad Could Follow Gilead's Or Mylan's Route In Drug Price Battle
03:34PM  TIMEWARNER-M&A/AT&T-LOANS-Market welcomes AT&T's $40 bln Time Warner loan Reuters
02:56PM  What Presidential Election? Deal Making Has Biggest Week Since 1999 at The Wall Street Journal
11:30AM  Biosimilars May Pose a Threat to Roches Herceptin
11:04AM  Eliquis Proving to Be a Major Growth Driver for Pfizer This Year
10:28AM  Healthcare ETFs: Gain or Pain Ahead in Q3 Earnings?
10:05AM  Treating Epilepsy Is One of Pfizers Solid Growth Prospects
08:20AM  Bad Headlines and Huge Deals Put Top Dividend Stocks on Sale at 24/7 Wall St.
08:06AM  Analyst Recommendations for Pfizer and Its Peers in 2016
12:00AM  [$$] A CEO's primer on how to manage under pressure at Financial Times
Oct-23-16 10:23AM  The Biggest Mergers & Acquisitions In The U.S. at Investopedia
Oct-21-16 05:03PM  Sanders urges Californians to approve drug price ballot measure Reuters
04:26PM  Billionaire Ken Fisher Loves These Dividend Stocks at Insider Monkey
11:55AM  FDA Approves Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Advanced Prostate Cancer PR Newswire
10:08AM  Advent, Bain gain edge in bid for Pfizer's Brazil venture -sources
09:30AM  The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals
07:45AM  Why Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma at 24/7 Wall St.
Oct-20-16 10:29AM  7 Drug Stocks to Consider as Biosimilars Pick Up Pace
10:24AM  Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc at Motley Fool
08:00AM  Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy PR Newswire
Oct-19-16 06:02PM  CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine) Business Wire
05:38PM  Seven New Stocks in My Purloined Portfolio
10:27AM  WHO seeks new mechanism for crisis vaccine supplies at low cost Reuters
08:38AM  Key Takeaways from JNJ's Q3 Call: Remicade, Pipeline, Acquisitions
08:00AM  Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection Business Wire
12:11AM  [$$] Johnson & Johnson Brushes Off Looming Biosimilar Competition, Posts Solid Results at The Wall Street Journal
Oct-18-16 05:21PM  Eli Lillys 3Q16 Earnings: What to Expect
04:42PM  Netflix and UnitedHealth climb; IBM and Amaya stumble
02:19PM  Pfizer's Remicade Rudeness Shouldn't Faze J&J at Bloomberg
02:15PM  Johnson & Johnson: 3 Reasons the Selloff is Overblown at
01:35PM  J&J shares lose ground on fears of Pfizer's answer to Remicade
12:13PM  [$$] J&J Brushes Off Looming Biosimilar Competition at The Wall Street Journal
12:06PM  [$$] J&J prepares for drug price war with Pfizer at Financial Times
11:59AM  Johnson & Johnson tops 3Q Street view but shares decline
11:49AM  Why Johnson & Johnson is Tanking at
10:54AM  Why Visa, Johnson and Johnson, Pfizer, and Two Other Stocks Are in Spotlight Today at Insider Monkey
10:42AM  Pharma giants poised to battle over biosimilar medicine at
09:56AM  J&J says pharma future bright, despite threat to Remicade
09:41AM  Pfizer to Launch Remicade Biosimilar in U.S. in November
08:31AM  Pharma giants poised for biosimilar battle at
07:37AM  Alzheimer's Remains a Top Priority for Big Pharma at Motley Fool
Oct-17-16 06:50PM  [$$] Pfizer Plans to Launch Remicade Biosimilar in November at The Wall Street Journal
06:16PM  Pfizer to launch cheaper version of J&J immune drug Remicade
06:01PM  Pfizer to start shipping biosimilar version of J&J's Remicade in November Reuters
04:49PM  Pfizer set to start shipping Remicade biosimilar next month Reuters
04:13PM  Eli Lilly, AbbVie Top 2017 Rankings; Pfizer, AstraZeneca Flailing
04:05PM  Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb) Business Wire
02:58PM  Pfizer Refuses to Go the Spinoff Route
01:56PM  What to expect from Johnson & Johnson earnings at MarketWatch
11:04AM  Johnson & Johnsons Expected Profitability in 3Q16
09:30AM  The Zacks Analyst Blog Highlights: Mylan, Pfizer, Roche, Merck and Bristol-Myers
08:36AM  Pfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis at Motley Fool
08:05AM  Could Johnson & Johnsons Earnings Grow in 3Q16?
06:00AM  Making Sense of Merger-Arbitrage Funds at Morningstar
Oct-15-16 10:30AM  Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016 Business Wire
Oct-14-16 06:04PM  How Will Johnson & Johnson Fare Revenue-Wise in 3Q16?
04:42PM  Is Opko Health On the Cusp of a Big Year? at Motley Fool
02:30PM  No, Virginia, the M&A market has not gone into a death spiral
11:04AM  How Much Is Pfizers Return Potential?
11:00AM  3 Big-Cap Stocks That Are Growing Again at Motley Fool
10:10AM  Johnson & Johnsons 3Q16 Earnings: What to Expect
10:04AM  Pfizers Divestment of Hospira Infusion Systems
09:43AM  A Guide to Conservative Income Producing Option Strategies for Dividend Stocks at Insider Monkey
09:22AM  Pharma Stock Roundup: Mylan in EpiPen Medicaid Settlement, ESMO Data in Focus
08:04AM  Four Key Deals: Analyzing Pfizers Impending Growth
Oct-13-16 06:08PM  US Market Indexes Lower on Thursday
05:32PM  Treasury takes its latest step to keep corporate taxes in the US at CNBC
05:04PM  Valeant Thinks It Will Hit Its Financial Targets in 2016
05:00PM  Exelixis Goes for It at Motley Fool
04:29PM  Pfizer Will Likely Overpay For M&A Post-Allergan Breakup Flop: Jeffries
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; and collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., Merck KGaA, and Transgene S.A. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM